AER label comprehension study
This article was originally published in The Tan Sheet
Executive Summary
FDA has proposed a consumer comprehension study be conducted on labeling statement alternatives relating to AERs for Rx and OTC drugs, the agency announces in the Federal Register Feb. 2. The idea for the study came about as a result of an FDA proposed rule in 2004 which required all OTCs approved under an NDA or ANDA to add a toll-free number and other statements to product labeling for adverse event reporting purposes (1"The Tan Sheet" April 26, 2004 p. 14). FDA conducted focus groups to narrow the field of potential labeling statement alternatives in response to comments recommending changes to the statements. The experimental study the agency now plans will require participants to view a statement on an Rx or OTC bottle and then answer a series of questions. The information will be gathered via the Internet by an external research organization...
You may also be interested in...
Toll-Free AER Number For Sec. 505 OTCs To Be On Labels One Year After Rule
FDA is planning to allow OTCs approved under an NDA or ANDA up to one year to add a toll-free number to labeling for adverse event reports, according to a 1proposed rule published in the April 22 Federal Register
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.